Field labs saved from ORA ax
This article was originally published in The Silver Sheet
Executive Summary
FDA's Office of Regulatory Affairs (ORA) is backing off plans to close seven field labs as part of an ongoing reorganization. Associate Commissioner for Regulatory Affairs Margaret O'K. Glavin sent ORA staff an e-mail Aug. 17 that said she was "canceling plans for the rollout of all changes in our organizational structure." However, she said this move would provide "additional time" to "take a fresh look at the challenges facing" the office. ORA's field labs inspect and analyze devices, food, drugs, animal medications and feeds, and other health products. The decision to call off the closure of seven of the office's 13 field labs was first indicated in an Aug. 1 e-mail to staff
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.